TY  - JOUR
AU  - Cassetta, Luca
AU  - Bruderek, Kirsten
AU  - Skrzeczynska-Moncznik, Joanna
AU  - Osiecka, Oktawia
AU  - Hu, Xiaoying
AU  - Rundgren, Ida Marie
AU  - Lin, Ang
AU  - Santegoets, Kim
AU  - Horzum, Utku
AU  - Godinho-Santos, Ana
AU  - Zelinskyy, Gennadiy
AU  - Garcia-Tellez, Thalia
AU  - Bjelica, Sunčica
AU  - Taciak, Bartlomiej
AU  - Kittang, Astrid Olsnes
AU  - Hoeing, Benedikt
AU  - Lang, Stephan
AU  - Dixon, Michael
AU  - Mueller, Verena
AU  - Utikal, Jochen Sven
AU  - Karakoc, Derya
AU  - Yilmaz, Kerim Bora
AU  - Gorka, Emilia
AU  - Bodnar, Lubomir
AU  - Anastasiou, Olympia Evdoxia
AU  - Bourgeois, Christine
AU  - Badura, Robert
AU  - Kapinska-Mrowiecka, Monika
AU  - Gotić, Mirjana
AU  - ter Laan, Mark
AU  - Kers-Rebel, Esther
AU  - Krol, Magdalena
AU  - Santibanez, Juan F.
AU  - Mueller-Trutwin, Michaela
AU  - Dittmer, Ulf
AU  - de Sousa, Ana Espada
AU  - Esendagli, Gunes
AU  - Adema, Gosse
AU  - Lore, Karin
AU  - Ersvaer, Elisabeth
AU  - Umansky, Viktor
AU  - Pollard, Jeffrey W.
AU  - Cichy, Joanna
AU  - Brandau, Sven
PY  - 2020
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/994
AB  - Background Myeloid-derived suppressor cells (MDSC) are a functional myeloid cell subset that includes myeloid cells with immune suppressive properties. The presence of MDSC has been reported in the peripheral blood of patients with several malignant and non-malignant diseases. So far, direct comparison of MDSC across different diseases and Centers is hindered by technical pitfalls and a lack of standardized methodology. To overcome this issue, we formed a network through the COST Action Mye-EUNITER () with the goal to standardize and facilitate the comparative analysis of human circulating MDSC in cancer, inflammation and infection. In this manuscript, we present the results of the multicenter study Mye-EUNITER MDSC Monitoring Initiative, that involved 13 laboratories and compared circulating MDSC subsets across multiple diseases, using a common protocol for the isolation, identification and characterization of these cells. Methods We developed, tested, executed and optimized a standard operating procedure for the isolation and immunophenotyping of MDSC using blood from healthy donors. We applied this procedure to the blood of almost 400 patients and controls with different solid tumors and non-malignant diseases. The latter included viral infections such as HIV and hepatitis B virus, but also psoriasis and cardiovascular disorders. Results We observed that the frequency of MDSC in healthy donors varied substantially between centers and was influenced by technical aspects such as the anticoagulant and separation method used. Expansion of polymorphonuclear (PMN)-MDSC exceeded the expansion of monocytic MDSC (M-MDSC) in five out of six solid tumors. PMN-MDSC expansion was more pronounced in cancer compared with infection and inflammation. Programmed death-ligand 1 was primarily expressed in M-MDSC and e-MDSC and was not upregulated as a consequence of disease. LOX-1 expression was confined to PMN-MDSC. Conclusions This study provides improved technical protocols and workflows for the multi-center analysis of circulating human MDSC subsets. Application of these workflows revealed a predominant expansion of PMN-MDSC in solid tumors that exceeds expansion in chronic infection and inflammation.
PB  - BMJ Publishing Group, London
T2  - Journal for Immunotherapy of Cancer
T1  - Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation
IS  - 2
SP  - e001223
VL  - 8
DO  - 10.1136/jitc-2020-001223
ER  - 

@article{
author = "Cassetta, Luca and Bruderek, Kirsten and Skrzeczynska-Moncznik, Joanna and Osiecka, Oktawia and Hu, Xiaoying and Rundgren, Ida Marie and Lin, Ang and Santegoets, Kim and Horzum, Utku and Godinho-Santos, Ana and Zelinskyy, Gennadiy and Garcia-Tellez, Thalia and Bjelica, Sunčica and Taciak, Bartlomiej and Kittang, Astrid Olsnes and Hoeing, Benedikt and Lang, Stephan and Dixon, Michael and Mueller, Verena and Utikal, Jochen Sven and Karakoc, Derya and Yilmaz, Kerim Bora and Gorka, Emilia and Bodnar, Lubomir and Anastasiou, Olympia Evdoxia and Bourgeois, Christine and Badura, Robert and Kapinska-Mrowiecka, Monika and Gotić, Mirjana and ter Laan, Mark and Kers-Rebel, Esther and Krol, Magdalena and Santibanez, Juan F. and Mueller-Trutwin, Michaela and Dittmer, Ulf and de Sousa, Ana Espada and Esendagli, Gunes and Adema, Gosse and Lore, Karin and Ersvaer, Elisabeth and Umansky, Viktor and Pollard, Jeffrey W. and Cichy, Joanna and Brandau, Sven",
year = "2020",
abstract = "Background Myeloid-derived suppressor cells (MDSC) are a functional myeloid cell subset that includes myeloid cells with immune suppressive properties. The presence of MDSC has been reported in the peripheral blood of patients with several malignant and non-malignant diseases. So far, direct comparison of MDSC across different diseases and Centers is hindered by technical pitfalls and a lack of standardized methodology. To overcome this issue, we formed a network through the COST Action Mye-EUNITER () with the goal to standardize and facilitate the comparative analysis of human circulating MDSC in cancer, inflammation and infection. In this manuscript, we present the results of the multicenter study Mye-EUNITER MDSC Monitoring Initiative, that involved 13 laboratories and compared circulating MDSC subsets across multiple diseases, using a common protocol for the isolation, identification and characterization of these cells. Methods We developed, tested, executed and optimized a standard operating procedure for the isolation and immunophenotyping of MDSC using blood from healthy donors. We applied this procedure to the blood of almost 400 patients and controls with different solid tumors and non-malignant diseases. The latter included viral infections such as HIV and hepatitis B virus, but also psoriasis and cardiovascular disorders. Results We observed that the frequency of MDSC in healthy donors varied substantially between centers and was influenced by technical aspects such as the anticoagulant and separation method used. Expansion of polymorphonuclear (PMN)-MDSC exceeded the expansion of monocytic MDSC (M-MDSC) in five out of six solid tumors. PMN-MDSC expansion was more pronounced in cancer compared with infection and inflammation. Programmed death-ligand 1 was primarily expressed in M-MDSC and e-MDSC and was not upregulated as a consequence of disease. LOX-1 expression was confined to PMN-MDSC. Conclusions This study provides improved technical protocols and workflows for the multi-center analysis of circulating human MDSC subsets. Application of these workflows revealed a predominant expansion of PMN-MDSC in solid tumors that exceeds expansion in chronic infection and inflammation.",
publisher = "BMJ Publishing Group, London",
journal = "Journal for Immunotherapy of Cancer",
title = "Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation",
number = "2",
pages = "e001223",
volume = "8",
doi = "10.1136/jitc-2020-001223"
}

Cassetta, L., Bruderek, K., Skrzeczynska-Moncznik, J., Osiecka, O., Hu, X., Rundgren, I. M., Lin, A., Santegoets, K., Horzum, U., Godinho-Santos, A., Zelinskyy, G., Garcia-Tellez, T., Bjelica, S., Taciak, B., Kittang, A. O., Hoeing, B., Lang, S., Dixon, M., Mueller, V., Utikal, J. S., Karakoc, D., Yilmaz, K. B., Gorka, E., Bodnar, L., Anastasiou, O. E., Bourgeois, C., Badura, R., Kapinska-Mrowiecka, M., Gotić, M., ter Laan, M., Kers-Rebel, E., Krol, M., Santibanez, J. F., Mueller-Trutwin, M., Dittmer, U., de Sousa, A. E., Esendagli, G., Adema, G., Lore, K., Ersvaer, E., Umansky, V., Pollard, J. W., Cichy, J.,& Brandau, S.. (2020). Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation. in Journal for Immunotherapy of Cancer
BMJ Publishing Group, London., 8(2), e001223.
https://doi.org/10.1136/jitc-2020-001223

Cassetta L, Bruderek K, Skrzeczynska-Moncznik J, Osiecka O, Hu X, Rundgren IM, Lin A, Santegoets K, Horzum U, Godinho-Santos A, Zelinskyy G, Garcia-Tellez T, Bjelica S, Taciak B, Kittang AO, Hoeing B, Lang S, Dixon M, Mueller V, Utikal JS, Karakoc D, Yilmaz KB, Gorka E, Bodnar L, Anastasiou OE, Bourgeois C, Badura R, Kapinska-Mrowiecka M, Gotić M, ter Laan M, Kers-Rebel E, Krol M, Santibanez JF, Mueller-Trutwin M, Dittmer U, de Sousa AE, Esendagli G, Adema G, Lore K, Ersvaer E, Umansky V, Pollard JW, Cichy J, Brandau S. Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation. in Journal for Immunotherapy of Cancer. 2020;8(2):e001223.
doi:10.1136/jitc-2020-001223 .

Cassetta, Luca, Bruderek, Kirsten, Skrzeczynska-Moncznik, Joanna, Osiecka, Oktawia, Hu, Xiaoying, Rundgren, Ida Marie, Lin, Ang, Santegoets, Kim, Horzum, Utku, Godinho-Santos, Ana, Zelinskyy, Gennadiy, Garcia-Tellez, Thalia, Bjelica, Sunčica, Taciak, Bartlomiej, Kittang, Astrid Olsnes, Hoeing, Benedikt, Lang, Stephan, Dixon, Michael, Mueller, Verena, Utikal, Jochen Sven, Karakoc, Derya, Yilmaz, Kerim Bora, Gorka, Emilia, Bodnar, Lubomir, Anastasiou, Olympia Evdoxia, Bourgeois, Christine, Badura, Robert, Kapinska-Mrowiecka, Monika, Gotić, Mirjana, ter Laan, Mark, Kers-Rebel, Esther, Krol, Magdalena, Santibanez, Juan F., Mueller-Trutwin, Michaela, Dittmer, Ulf, de Sousa, Ana Espada, Esendagli, Gunes, Adema, Gosse, Lore, Karin, Ersvaer, Elisabeth, Umansky, Viktor, Pollard, Jeffrey W., Cichy, Joanna, Brandau, Sven, "Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation" in Journal for Immunotherapy of Cancer, 8, no. 2 (2020):e001223,
https://doi.org/10.1136/jitc-2020-001223 . .

TY  - JOUR
AU  - Bizymi, Nikoleta
AU  - Bjelica, Sunčica
AU  - Kittang, Astrid Olsnes
AU  - Mojsilović, Slavko
AU  - Velegraki, Maria
AU  - Pontikoglou, Charalampos
AU  - Roussel, Mikael
AU  - Ersvaer, Elisabeth
AU  - Santibanez, Juan F.
AU  - Lipoldova, Marie
AU  - Papadaki, Helen A.
PY  - 2019
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/962
AB  - Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of immature myeloid cells that exist at very low numbers in healthy subjects but can expand significantly in malignant, infectious, and chronic inflammatory diseases. These cells are characterized as early-MDSCs, monocytic-MDSCs, and polymorphonuclear-MDSCs and can be studied on the basis of their immunophenotypic characteristics and their functional properties to suppress T-cell activation and proliferation. MDSCs have emerged as important contributors to tumor expansion and chronic inflammation progression by inducing immunosuppressive mechanisms, angiogenesis and drug resistance. Most experimental and clinical studies concerning MDSCs have been mainly focused on solid tumors. In recent years, however, the implication of MDSCs in the immune dysregulation associated with hematologic malignancies, immune-mediated cytopenias and allogeneic hemopoietic stem cell transplantation has been documented and the potential role of these cells as biomarkers and therapeutic targets has started to attract a particular interest in hematology. The elucidation of the molecular and signaling pathways associated with the generation, expansion and function of MDSCs in malignant and immune-mediated hematologic diseases and the clarification of mechanisms related to the circulation and the crosstalk of MDSCs with malignant cells and other components of the immune system are anticipated to lead to novel therapeutic strategies. This review summarizes all available evidence on the implication of MDSCs in hematologic diseases highlighting the challenges and perspectives arising from this novel field of research.
PB  - Lippincott Williams & Wilkins, Philadelphia
T2  - Hemasphere
T1  - Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets
IS  - 1
VL  - 3
DO  - 10.1097/HS9.0000000000000168
ER  - 

@article{
author = "Bizymi, Nikoleta and Bjelica, Sunčica and Kittang, Astrid Olsnes and Mojsilović, Slavko and Velegraki, Maria and Pontikoglou, Charalampos and Roussel, Mikael and Ersvaer, Elisabeth and Santibanez, Juan F. and Lipoldova, Marie and Papadaki, Helen A.",
year = "2019",
abstract = "Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of immature myeloid cells that exist at very low numbers in healthy subjects but can expand significantly in malignant, infectious, and chronic inflammatory diseases. These cells are characterized as early-MDSCs, monocytic-MDSCs, and polymorphonuclear-MDSCs and can be studied on the basis of their immunophenotypic characteristics and their functional properties to suppress T-cell activation and proliferation. MDSCs have emerged as important contributors to tumor expansion and chronic inflammation progression by inducing immunosuppressive mechanisms, angiogenesis and drug resistance. Most experimental and clinical studies concerning MDSCs have been mainly focused on solid tumors. In recent years, however, the implication of MDSCs in the immune dysregulation associated with hematologic malignancies, immune-mediated cytopenias and allogeneic hemopoietic stem cell transplantation has been documented and the potential role of these cells as biomarkers and therapeutic targets has started to attract a particular interest in hematology. The elucidation of the molecular and signaling pathways associated with the generation, expansion and function of MDSCs in malignant and immune-mediated hematologic diseases and the clarification of mechanisms related to the circulation and the crosstalk of MDSCs with malignant cells and other components of the immune system are anticipated to lead to novel therapeutic strategies. This review summarizes all available evidence on the implication of MDSCs in hematologic diseases highlighting the challenges and perspectives arising from this novel field of research.",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Hemasphere",
title = "Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets",
number = "1",
volume = "3",
doi = "10.1097/HS9.0000000000000168"
}

Bizymi, N., Bjelica, S., Kittang, A. O., Mojsilović, S., Velegraki, M., Pontikoglou, C., Roussel, M., Ersvaer, E., Santibanez, J. F., Lipoldova, M.,& Papadaki, H. A.. (2019). Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets. in Hemasphere
Lippincott Williams & Wilkins, Philadelphia., 3(1).
https://doi.org/10.1097/HS9.0000000000000168

Bizymi N, Bjelica S, Kittang AO, Mojsilović S, Velegraki M, Pontikoglou C, Roussel M, Ersvaer E, Santibanez JF, Lipoldova M, Papadaki HA. Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets. in Hemasphere. 2019;3(1).
doi:10.1097/HS9.0000000000000168 .

Bizymi, Nikoleta, Bjelica, Sunčica, Kittang, Astrid Olsnes, Mojsilović, Slavko, Velegraki, Maria, Pontikoglou, Charalampos, Roussel, Mikael, Ersvaer, Elisabeth, Santibanez, Juan F., Lipoldova, Marie, Papadaki, Helen A., "Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets" in Hemasphere, 3, no. 1 (2019),
https://doi.org/10.1097/HS9.0000000000000168 . .

TY  - JOUR
AU  - Umansky, Viktor
AU  - Adema, Gosse J.
AU  - Baran, Jaroslaw
AU  - Brandau, Sven
AU  - Van Ginderachter, Jo A.
AU  - Hu, Xiaoying
AU  - Jablonska, Jadwiga
AU  - Mojsilović, Slavko
AU  - Papadaki, Helen A.
AU  - de Coana, Yago Pico
AU  - Santegoets, Kim
AU  - Santibanez, Juan F.
AU  - Serre, Karine
AU  - Si, Yu
AU  - Sieminska, Isabela
AU  - Velegraki, Maria
AU  - Fridlender, Zvi G.
PY  - 2019
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/964
AB  - Mounting evidence has accumulated on the critical role of the different myeloid cells in the regulation of the cancerous process, and in particular in the modulation of the immune reaction to cancer. Myeloid cells are a major component of host cells infiltrating tumors, interacting with each other, with tumor cells and other stromal cells, and demonstrating a prominent plasticity. We describe here various myeloid regulatory cells (MRCs) in mice and human as well as their relevant therapeutic targets. We first address the role of the monocytes and macrophages that can contribute to angiogenesis, immunosuppression and metastatic dissemination. Next, we discuss the differential role of neutrophil subsets in tumor development, enhancing the dual and sometimes contradicting role of these cells. A heterogeneous population of immature myeloid cells, MDSCs, was shown to be generated and accumulated during tumor progression as well as to be an important player in cancer-related immune suppression. Lastly, we discuss the role of myeloid DCs, which can either contribute to effective anti-tumor responses or play a more regulatory role. We believe that MRCs play a critical role in cancer-related immune regulation and suggest that future anti-cancer therapies will focus on these abundant cells.
PB  - Springer, New York
T2  - Cancer Immunology Immunotherapy
T1  - Interactions among myeloid regulatory cells in cancer
EP  - 660
IS  - 4
SP  - 645
VL  - 68
DO  - 10.1007/s00262-018-2200-6
ER  - 

@article{
author = "Umansky, Viktor and Adema, Gosse J. and Baran, Jaroslaw and Brandau, Sven and Van Ginderachter, Jo A. and Hu, Xiaoying and Jablonska, Jadwiga and Mojsilović, Slavko and Papadaki, Helen A. and de Coana, Yago Pico and Santegoets, Kim and Santibanez, Juan F. and Serre, Karine and Si, Yu and Sieminska, Isabela and Velegraki, Maria and Fridlender, Zvi G.",
year = "2019",
abstract = "Mounting evidence has accumulated on the critical role of the different myeloid cells in the regulation of the cancerous process, and in particular in the modulation of the immune reaction to cancer. Myeloid cells are a major component of host cells infiltrating tumors, interacting with each other, with tumor cells and other stromal cells, and demonstrating a prominent plasticity. We describe here various myeloid regulatory cells (MRCs) in mice and human as well as their relevant therapeutic targets. We first address the role of the monocytes and macrophages that can contribute to angiogenesis, immunosuppression and metastatic dissemination. Next, we discuss the differential role of neutrophil subsets in tumor development, enhancing the dual and sometimes contradicting role of these cells. A heterogeneous population of immature myeloid cells, MDSCs, was shown to be generated and accumulated during tumor progression as well as to be an important player in cancer-related immune suppression. Lastly, we discuss the role of myeloid DCs, which can either contribute to effective anti-tumor responses or play a more regulatory role. We believe that MRCs play a critical role in cancer-related immune regulation and suggest that future anti-cancer therapies will focus on these abundant cells.",
publisher = "Springer, New York",
journal = "Cancer Immunology Immunotherapy",
title = "Interactions among myeloid regulatory cells in cancer",
pages = "660-645",
number = "4",
volume = "68",
doi = "10.1007/s00262-018-2200-6"
}

Umansky, V., Adema, G. J., Baran, J., Brandau, S., Van Ginderachter, J. A., Hu, X., Jablonska, J., Mojsilović, S., Papadaki, H. A., de Coana, Y. P., Santegoets, K., Santibanez, J. F., Serre, K., Si, Y., Sieminska, I., Velegraki, M.,& Fridlender, Z. G.. (2019). Interactions among myeloid regulatory cells in cancer. in Cancer Immunology Immunotherapy
Springer, New York., 68(4), 645-660.
https://doi.org/10.1007/s00262-018-2200-6

Umansky V, Adema GJ, Baran J, Brandau S, Van Ginderachter JA, Hu X, Jablonska J, Mojsilović S, Papadaki HA, de Coana YP, Santegoets K, Santibanez JF, Serre K, Si Y, Sieminska I, Velegraki M, Fridlender ZG. Interactions among myeloid regulatory cells in cancer. in Cancer Immunology Immunotherapy. 2019;68(4):645-660.
doi:10.1007/s00262-018-2200-6 .

Umansky, Viktor, Adema, Gosse J., Baran, Jaroslaw, Brandau, Sven, Van Ginderachter, Jo A., Hu, Xiaoying, Jablonska, Jadwiga, Mojsilović, Slavko, Papadaki, Helen A., de Coana, Yago Pico, Santegoets, Kim, Santibanez, Juan F., Serre, Karine, Si, Yu, Sieminska, Isabela, Velegraki, Maria, Fridlender, Zvi G., "Interactions among myeloid regulatory cells in cancer" in Cancer Immunology Immunotherapy, 68, no. 4 (2019):645-660,
https://doi.org/10.1007/s00262-018-2200-6 . .

TY  - JOUR
AU  - Bruger, Annika M.
AU  - Dorhoi, Anca
AU  - Esendagli, Gunes
AU  - Barczyk-Kahlert, Katarzyna
AU  - van der Bruggen, Pierre
AU  - Lipoldova, Marie
AU  - Perecko, Tomas
AU  - Santibanez, Juan F.
AU  - Saraiva, Margarida
AU  - Van Ginderachter, Jo A.
AU  - Brandau, Sven
PY  - 2019
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/947
AB  - Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of mononuclear and polymorphonuclear myeloid cells, which are present at very low numbers in healthy subjects, but can expand substantially under disease conditions. Depending on disease type and stage, MDSC comprise varying amounts of immature and mature differentiation stages of myeloid cells. Validated unique phenotypic markers for MDSC are still lacking. Therefore, the functional analysis of these cells is of central importance for their identification and characterization. Various disease-promoting and immunosuppressive functions of MDSC are reported in the literature. Among those, the capacity to modulate the activity of T cells is by far the most often used and best-established read-out system. In this review, we critically evaluate the assays available for the functional analysis of human and murine MDSC under in vitro and in vivo conditions. We also discuss critical issues and controls associated with those assays. We aim at providing suggestions and recommendations useful for the contemporary biological characterization of MDSC.
PB  - Springer, New York
T2  - Cancer Immunology Immunotherapy
T1  - How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions
EP  - 644
IS  - 4
SP  - 631
VL  - 68
DO  - 10.1007/s00262-018-2170-8
ER  - 

@article{
author = "Bruger, Annika M. and Dorhoi, Anca and Esendagli, Gunes and Barczyk-Kahlert, Katarzyna and van der Bruggen, Pierre and Lipoldova, Marie and Perecko, Tomas and Santibanez, Juan F. and Saraiva, Margarida and Van Ginderachter, Jo A. and Brandau, Sven",
year = "2019",
abstract = "Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of mononuclear and polymorphonuclear myeloid cells, which are present at very low numbers in healthy subjects, but can expand substantially under disease conditions. Depending on disease type and stage, MDSC comprise varying amounts of immature and mature differentiation stages of myeloid cells. Validated unique phenotypic markers for MDSC are still lacking. Therefore, the functional analysis of these cells is of central importance for their identification and characterization. Various disease-promoting and immunosuppressive functions of MDSC are reported in the literature. Among those, the capacity to modulate the activity of T cells is by far the most often used and best-established read-out system. In this review, we critically evaluate the assays available for the functional analysis of human and murine MDSC under in vitro and in vivo conditions. We also discuss critical issues and controls associated with those assays. We aim at providing suggestions and recommendations useful for the contemporary biological characterization of MDSC.",
publisher = "Springer, New York",
journal = "Cancer Immunology Immunotherapy",
title = "How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions",
pages = "644-631",
number = "4",
volume = "68",
doi = "10.1007/s00262-018-2170-8"
}

Bruger, A. M., Dorhoi, A., Esendagli, G., Barczyk-Kahlert, K., van der Bruggen, P., Lipoldova, M., Perecko, T., Santibanez, J. F., Saraiva, M., Van Ginderachter, J. A.,& Brandau, S.. (2019). How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions. in Cancer Immunology Immunotherapy
Springer, New York., 68(4), 631-644.
https://doi.org/10.1007/s00262-018-2170-8

Bruger AM, Dorhoi A, Esendagli G, Barczyk-Kahlert K, van der Bruggen P, Lipoldova M, Perecko T, Santibanez JF, Saraiva M, Van Ginderachter JA, Brandau S. How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions. in Cancer Immunology Immunotherapy. 2019;68(4):631-644.
doi:10.1007/s00262-018-2170-8 .

Bruger, Annika M., Dorhoi, Anca, Esendagli, Gunes, Barczyk-Kahlert, Katarzyna, van der Bruggen, Pierre, Lipoldova, Marie, Perecko, Tomas, Santibanez, Juan F., Saraiva, Margarida, Van Ginderachter, Jo A., Brandau, Sven, "How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions" in Cancer Immunology Immunotherapy, 68, no. 4 (2019):631-644,
https://doi.org/10.1007/s00262-018-2170-8 . .

TY  - JOUR
AU  - Pokimica, Biljana
AU  - Garcia-Conesa, Maria-Teresa
PY  - 2018
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/861
AB  - Pre-clinical cell and animal nutrigenomic studies have long suggested the modulation of the transcription of multiple gene targets in cells and tissues as a potential molecular mechanism of action underlying the beneficial effects attributed to plant-derived bioactive compounds. To try to demonstrate these molecular effects in humans, a considerable number of clinical trials have now explored the changes in the expression levels of selected genes in various human cell and tissue samples following intervention with different dietary sources of bioactive compounds. In this review, we have compiled a total of 75 human studies exploring gene expression changes using quantitative reverse transcription PCR (RT-qPCR). We have critically appraised the study design and methodology used as well as the gene expression results reported. We herein pinpoint some of the main drawbacks and gaps in the experimental strategies applied, as well as the high interindividual variability of the results and the limited evidence supporting some of the investigated genes as potential responsive targets. We reinforce the need to apply normalized procedures and follow well-established methodological guidelines in future studies in order to achieve improved and reliable results that would allow for more relevant and biologically meaningful results.
PB  - MDPI, Basel
T2  - Nutrients
T1  - Critical Evaluation of Gene Expression Changes in Human Tissues in Response to Supplementation with Dietary Bioactive Compounds: Moving Towards Better-Quality Studies
IS  - 7
VL  - 10
DO  - 10.3390/nu10070807
ER  - 

@article{
author = "Pokimica, Biljana and Garcia-Conesa, Maria-Teresa",
year = "2018",
abstract = "Pre-clinical cell and animal nutrigenomic studies have long suggested the modulation of the transcription of multiple gene targets in cells and tissues as a potential molecular mechanism of action underlying the beneficial effects attributed to plant-derived bioactive compounds. To try to demonstrate these molecular effects in humans, a considerable number of clinical trials have now explored the changes in the expression levels of selected genes in various human cell and tissue samples following intervention with different dietary sources of bioactive compounds. In this review, we have compiled a total of 75 human studies exploring gene expression changes using quantitative reverse transcription PCR (RT-qPCR). We have critically appraised the study design and methodology used as well as the gene expression results reported. We herein pinpoint some of the main drawbacks and gaps in the experimental strategies applied, as well as the high interindividual variability of the results and the limited evidence supporting some of the investigated genes as potential responsive targets. We reinforce the need to apply normalized procedures and follow well-established methodological guidelines in future studies in order to achieve improved and reliable results that would allow for more relevant and biologically meaningful results.",
publisher = "MDPI, Basel",
journal = "Nutrients",
title = "Critical Evaluation of Gene Expression Changes in Human Tissues in Response to Supplementation with Dietary Bioactive Compounds: Moving Towards Better-Quality Studies",
number = "7",
volume = "10",
doi = "10.3390/nu10070807"
}

Pokimica, B.,& Garcia-Conesa, M.. (2018). Critical Evaluation of Gene Expression Changes in Human Tissues in Response to Supplementation with Dietary Bioactive Compounds: Moving Towards Better-Quality Studies. in Nutrients
MDPI, Basel., 10(7).
https://doi.org/10.3390/nu10070807

Pokimica B, Garcia-Conesa M. Critical Evaluation of Gene Expression Changes in Human Tissues in Response to Supplementation with Dietary Bioactive Compounds: Moving Towards Better-Quality Studies. in Nutrients. 2018;10(7).
doi:10.3390/nu10070807 .

Pokimica, Biljana, Garcia-Conesa, Maria-Teresa, "Critical Evaluation of Gene Expression Changes in Human Tissues in Response to Supplementation with Dietary Bioactive Compounds: Moving Towards Better-Quality Studies" in Nutrients, 10, no. 7 (2018),
https://doi.org/10.3390/nu10070807 . .